Geriatrics addresses the health needs of older adults, focusing on frailty, dementia, falls, and chronic disease management.
Send us all your questions or requests, and our expert team will assist you.
How do we treat a brain that has lost its ability to adapt? The treatment of depression in the elderly is no longer limited to “mood lifting”; it is an intensive process of Biological Restoration. At Liv Hospital, we move beyond the simple suppression of symptoms to address the underlying cellular decline. Our goal is to shift the brain from a state of inflammatory stress to a state of structural repair, utilizing the brain’s remaining neuro-plasticity to regain functional independence.
Treatment at this stage requires a delicate balance. We must stabilize the neurochemical environment while simultaneously protecting the aging body from the side effects of medication. By addressing the “Micro-environment” of the neuron improving cerebral blood flow and boosting growth proteins we provide the aging brain with the tools it needs to physically recover from the depressive state.
In geriatrics, the aging liver and kidneys process medications differently. Therefore, our pharmacological approach follows the “Start Low, Go Slow” rule. We prioritize medications with the cleanest safety profiles and the fewest drug-to-drug interactions. The objective is to stabilize neurotransmitters like Serotonin and Norepinephrine without inducing secondary complications such as orthostatic hypotension (leading to falls) or cognitive confusion.
Beyond imaging, the evaluation delves into the molecular realm with comprehensive biomarker panels. Blood, urine, and saliva are analyzed to assess a vast array of physiological metrics. Key among these is the evaluation of neurotrophic factors, such as Brain-Derived Neurotrophic Factor and Vascular Endothelial Growth Factor. Low levels of these proteins serve as critical indicators of the brain’s reduced capacity for repair and maintenance. Additionally, inflammatory markers such as C-reactive protein, homocysteine, and various interleukins are measured to determine the inflammatory burden on the brain.
This granular analysis allows the clinical team to diagnose inflammaging as a specific biological driver of the patient’s depressive symptoms. It separates biological depression from purely psychosocial causes and guides anti-inflammatory interventions. Furthermore, metabolic profiling is performed to assess insulin resistance, vitamin deficiencies, and mitochondrial markers. This ensures that any metabolic blockades preventing energy production in the brain are identified and addressed.
Genetic and epigenetic testing form another pillar of the diagnostic architecture. Understanding a patient’s genetic predispositions such as variations in the MTHFR gene, which affects methylation and neurotransmitter synthesis provides invaluable context regarding their susceptibility to mood disorders and their ability to metabolize medications. However, modern diagnostics go further, examining epigenetic markers that reveal how lifestyle and environment have influenced gene expression. This includes measuring telomere length to assess cellular biological age versus chronological age.
A patient with depression may exhibit accelerated cellular aging, a finding that immediately directs the care pathway toward aggressive anti-aging and regenerative interventions. This genomic insight transforms the diagnosis from a static label into a dynamic understanding of gene-environment interactions. It allows the clinician to see not just the genes the patient was born with, but also how those genes are behaving in real time, offering targets for intervention that can reverse negative epigenetic expression.
The evaluation of the neuro-endocrine system is exhaustive. The Hypothalamic-Pituitary-Adrenal axis, the body’s central stress response system, is assessed through diurnal cortisol testing. This reveals whether the patient is in a state of high-stress dominance or a state of adrenal exhaustion, both of which can manifest as profound depression. Furthermore, a full thyroid panel, sex hormone evaluation, and cardiovascular assessment are conducted. This is because hormonal imbalances and vascular dysfunctions often masquerade as, or exacerbate, mood disorders. In the geriatric population, distinguishing between a primary depressive disorder and a hormonal deficiency is a critical diagnostic step.
The gut-brain connection is evaluated through advanced microbiome analysis. By sequencing the DNA of gut flora, clinicians can identify dysbiosis an imbalance of beneficial and pathogenic bacteria that may be producing neurotoxins or failing to produce essential neurotransmitter precursors, such as serotonin. Additionally, testing for intestinal permeability helps identify potential sources of systemic inflammation that cross the blood-brain barrier. This aspect of the diagnosis highlights the philosophy that a healthy mind is dependent on a healthy gut environment.
Key components of the regenerative diagnostic suite include:
Biological repair must be supported by environmental stimulation. Psychosocial Re-engagement focuses on breaking the cycle of apathy and social withdrawal. We integrate behavioral activation therapies that help seniors reconnect with their surroundings, which in turn provides the sensory input necessary for neuro-plasticity.
Send us all your questions or requests, and our expert team will assist you.
As we age, the body’s metabolism slows down, and medications stay in the system longer. We use lower doses to achieve the same therapeutic effect while minimizing the risk of side effects like dizziness or confusion.
While some physical improvements (like better sleep) may happen in 1-2 weeks, the restorative changes in mood and cognitive clarity usually take 4 to 8 weeks as the brain physically repairs its connections.
Yes, but they must be chosen carefully. Certain classes of antidepressants are safer for the heart than others. Part of our care is coordinating with your cardiologist to ensure your treatment is safe for your entire system.
In cases of “Pseudo-dementia,” yes. When we treat the underlying depression and reduce neuro-inflammation, the “fog” clears, and memory, focus, and processing speed often improve significantly.
If standard treatments are not enough, we look deeper into vascular health or nutritional deficiencies. We may also adjust the protocol to include more intensive neurotrophic support or therapeutic lifestyle changes.
Your Comparison List (you must select at least 2 packages)
